5.35

0.74% -0.04

Ars Pharmaceuticals Inc (SPRY)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$5.39

Offen:

$5.35

24-Stunden-Volumen:

123.69K

Relative Volume:

0.06

Marktkapitalisierung:

$532.04M

Einnahmen:

$98.99M

Nettoeinkommen (Verlust:

$-197.98M

KGV:

-2.6727

EPS:

-2.0017

Netto-Cashflow:

$-175.32M

1W Leistung:

-8.08%

1M Leistung:

-13.15%

6M Leistung:

-40.88%

1J Leistung:

-48.16%

1-Tages-Spanne:

$5.30

$5.38

1-Wochen-Bereich:

$5.30

$5.90

52-Wochen-Spanne:

$4.9102

$13.15

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Firmenname

Ars Pharmaceuticals Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

858-771-9307

Adresse

11682 EL CAMINO REAL, SUITE 300, SAN DIEGO

Mitarbeiter

159

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

SPRY's Discussions on Twitter

Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SPRY Ars Pharmaceuticals Inc	5.35	536.02M	98.99M	-197.98M	-175.32M	-2.0017
VRTX Vertex Pharmaceuticals Inc	522.83	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	800.17	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,000.20	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.32	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.18	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-09	Eingeleitet	Northland Capital	Outperform
2025-11-04	Fortgesetzt	Roth Capital	Buy
2025-09-04	Eingeleitet	Roth Capital	Buy
2025-03-07	Eingeleitet	Scotiabank	Sector Outperform
2025-02-10	Eingeleitet	Oppenheimer	Outperform
2024-08-20	Eingeleitet	Cantor Fitzgerald	Overweight
2024-08-13	Hochstufung	Raymond James	Outperform → Strong Buy
2024-08-12	Bestätigt	Leerink Partners	Outperform
2024-07-25	Eingeleitet	Raymond James	Outperform
2024-03-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-20	Hochstufung	William Blair	Mkt Perform → Outperform
2023-09-20	Herabstufung	William Blair	Outperform → Mkt Perform
2023-01-31	Eingeleitet	Wedbush	Outperform
2023-01-03	Eingeleitet	William Blair	Outperform
2022-12-13	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten

07:00 AM

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

07:00 AM

Sep 07, 2026

symbol__ Stock Quote Price and Forecast - cnn.com

Sep 07, 2026

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com

Sep 07, 2026

Sep 06, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.

Sep 06, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun

Sep 06, 2026

Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY - The National Law Review

Sep 06, 2026

Sep 05, 2026

SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits

Sep 05, 2026

Sep 04, 2026

ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - ACCESS Newswire

Sep 04, 2026

Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan

Sep 04, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 04, 2026

Sep 03, 2026

Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire

Sep 03, 2026

ARS Pharmaceuticals (SPRY) insider lines up Sept. 3 stock sale after August trades - Stock Titan

Sep 03, 2026

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors t - The National Law Review

Sep 03, 2026

SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - morningstar.com

Sep 03, 2026

Sep 02, 2026

Chief commercial officer at ARS Pharma (SPRY) gets 1.0M stock options - Stock Titan

Sep 02, 2026

Insider at ARS Pharmaceuticals (NASDAQ: SPRY) plans another stock sale - Stock Titan

Sep 02, 2026

ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc. - TMX Newsfile

Sep 02, 2026

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact Levi & Korsinsky - PR Newswire

Sep 02, 2026

ARS Pharmaceuticals (SPRY) Institutional Ownership 2026 $SPRY - marketbeat.com

Sep 02, 2026

Sep 01, 2026

Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review

Sep 01, 2026

Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) - NewMediaWire

Sep 01, 2026

Repeat insider selling at ARS Pharma (SPRY) now includes a planned early-September trade - Stock Titan

Sep 01, 2026

Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Sep 01, 2026

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Sep 01, 2026

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Sep 01, 2026

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Sep 01, 2026

Aug 31, 2026

ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire

Aug 31, 2026

ARS Pharma (NASDAQ: SPRY) insider lines up new sale after August stock disposals - Stock Titan

Aug 31, 2026

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities - GlobeNewswire

Aug 31, 2026

SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharma - The National Law Review

Aug 31, 2026

Aug 28, 2026

ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel ... - Herald and News

Aug 28, 2026

Aug 27, 2026

Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026 - Barchart.com

Aug 27, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire

Aug 27, 2026

ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. - globenewswire.com

Aug 27, 2026

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - morningstar.com

Aug 27, 2026

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Inv - The National Law Review

Aug 27, 2026

Aug 26, 2026

Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire

Aug 26, 2026

Aug 25, 2026

ROSEN, NATIONAL TRIAL COUNSEL, Encourages ARS - GlobeNewswire

Aug 25, 2026

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 25, 2026

Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Hub ... - Herald and News

Aug 25, 2026

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Barchart.com

Aug 25, 2026

Aug 21, 2026

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance

Aug 21, 2026

SPRY Investors Have Rights – If You Lost Money Investing in - GlobeNewswire

Aug 21, 2026